Determining the presence of reliable change over time in multiple sclerosis: Evidence from the PASAT, adjusting-PSAT, and Stroop test

International Journal of MS Care

Volumn 15, Issue 4, 2013, Pages 170-178

  Barker Collo, Suzanne L ^a   Purdy, Suzanne C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892164398     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2013-007     Document Type: Article

References (35)

1. Portaccio E, Goretti B, Zipoli V, et al. Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery. Mult Scler. 2010;16:611-617.
2. Amato MP, Zipolo V, Portaccio E. Cognitive changes in multiple sclerosis. Exp Rev Neurother. 2008;8:1585-1596.
3. Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci. 2007;14:919-927.
4. Brassington JC, Marsh NV. Neuropsychological aspects of multiple sclerosis. Neuropsychol Rev. 1998;8:43-77.
5. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol. 2003;16:283-288.
6. Dineen RA, Vilisaar J, Hlinka J, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain. 2009;132:239-249.
7. De Sonneville LM, Boringa JB, Reuling IE, Lazeron RH, Ader HJ, Polman CH. Information processing characteristics in subtypes of multiple sclerosis. Neuropsychologia. 2002;40:1751-1765.
8. DeLuca J, Chelune GJ, Tulsky DS, Lengenfelder J, Chiaravalloti ND. Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J Clin Exp Neuropsychol. 2004;26:550-562.
9. Demaree HA, DeLuca J, Gaudino EA, Diamond BJ. Information processing speed-a key deficit in multiple sclerosis: implications for rehabilitation. J Neurol Neurosurg Psychiatry. 1999;67:661-663.
10. Snyder PJ, Cappelleri JC. Information processing speed deficits may be better correlated with the extent of white matter sclerotic lesions in multiple sclerosis than previously suspected. Brain Cogn. 2001;46:279-284.
11. Barak Y, Achirona A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur J Neurol. 2002;47:11-14.
12. Cutter GC, Baier ML, Rudick RA. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871-882.
13. Rudick RA, Antel J, Confavreaux C. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997;42:379-382.
14. Barker-Collo SL. Quality of life in multiple sclerosis: does information-processing speed have an independent effect? Arch Clin Neuropsychol. 2006;21:167-174.
15. Wise EA. Methods for analyzing psychotherapy outcomes: a review of clinical significance, reliable change, and recommendations for future directions. J Pers Assess. 2004;82:50-59.
16. Bauer S, Lambert MJ, Nielsen SL. Clinical significance methods: a comparison of statistical techniques. J Pers Assess. 2004;82:60-70.
17. Troster AI, Woods SP, Morgan EE. Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices. Arch Clin Neuropsychol. 2007;22:711-718.
18. Barber AP, Hach S, Tippett LJ, Ross L, Merry AF, Milsom P. Cerebral ischemic lesions on diffusion-weighted imaging are associated with neurocognitive decline after cardiac surgery. Stroke. 2008;39: 1427-1433.
19. Chelune GJ, Naugle RI, Lüders H, Sedlak J, Awad IA. Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology. 1993;7:41-52.
20. Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurolog Sci. 2005;228:71-74.
21. Rosti-Otajarvi E, Hamalainen P, Koivisto K, Hokkanen L. The reliability of the MSFC and its components. Acta Neurolog Scand. 2008;117:421-427.
22. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33: 1444-1452.
23. Shawaryn MA, Schiaffino KM, LaRocca NG, Johnston MV: Determinants of health-related quality of life in multiple sclerosis: the role of illness intrusiveness. Mult Scler. 2002;8:310-318.
24. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain. 2000;123:1027-1040.
25. Gronwall D. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977;44:367-373.
26. Royan J, Tombaugh TN, Rees L, Francise M. The Adjusting-Paced Serial Addition Test (Adjusting-PSAT): thresholds for speed of information processing as a function of stimulus modality and problem complexity. Arch Clin Neuropsychol. 2004;19:131-143.
27. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York, NY: Oxford University Press; 2006.
28. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd ed. New York, NY: Oxford University Press; 1998.
29. D'Souza M, Kappos L, Czaplinski A. Reconsidering clinical outcomes in multiple sclerosis: relapses, impairment, disability and beyond. J Neurol Sci. 2008;274:76-79.
30. Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? a comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord. 2011;4:281-296.
31. Barr W. Neuropsychological testing for assessment of treatment effects: methodologic issues. CNS Spectrum. 2002;7:304-306.
32. Frerichs R, Tuokko H. A comparison of methods for measuring cognitive change in older adults. Arch Clin Neuropsychol. 2005;20: 321-333.
33. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001;58:961-967.
34. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679-687.
35. Fischer J, Rudick R, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler. 1999;5:244-250.